The SGLT2 inhibitor empagliflozin (Jardiance) was approved by European regulators for treating adults with chronic kidney disease. The FDA is reviewing a new drug application for this indication.
The SGLT2 inhibitor didn t relieve congestion more effectively than a thiazide-like diuretic when added to furosemide in loop-diuretic–resistant patients with acute heart failure.
Management of heart failure focuses on avoiding reversible precipitants and optimizing guideline-directed therapy to lower mortality and hospitalizations.